A Study of Lerociclib in Women With Advanced Breast Cancer
Status:
Not yet recruiting
Trial end date:
2026-05-01
Target enrollment:
Participant gender:
Summary
This is a multicenter, single-arm, open-label study to evaluate the safety and efficacy of
lerociclib in combination with standard endocrine therapy in women with HR+/HER2- MBC.
The study population will consist of either newly diagnosed, treatment naïve women with
HR+/HER2- MBC (1L population) or women with HR+/HER2- MBC who have already progressed on
first line endocrine therapy such as tamoxifen, anastrozole, or letrozole (2L population).
All participants must either be postmenopausal or receiving active ovarian suppression
(goserelin).